Sprot, the 2$ target is just a way of saying this isn't going anywhere fast for the next 12 month. 2$ is the fare value being placed for IPCI right now, which is what's happening. The ratings does have impact on the stock. But we also have analysts that were bullish.
Politics are battling it out too. Big pharmas were spending a lot to push things in their favor. Getting states to mandate the use of ADF, getting FDA to endorse ADF. Putting into peoples minds that ADF will solve the problem. On the other hand, people are saying ADF doesn't solve the issue and there are no statistics that shows ADF reduce overdose, or lowers abuse and addiction.
Personally, the forces that's pushing ADF isn't going to stop and it seems FDA is on their side. That's too much stakes to lose and politics won't let that happen.
What IPCI got going that's different than any other company is PODRAS. That's what we want to see moving forward. If Odidi start publishing PODRAS trial results, we would see a whole lot more coverage.
News 
Market Data 
Discover 
